{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:10:42Z","timestamp":1779307842844,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA237806"],"award-info":[{"award-number":["K12CA237806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102556","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:12:49Z","timestamp":1775059969000},"page":"102556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States"],"prefix":"10.1016","volume":"24","author":[{"given":"Nikhil T.","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dattatraya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pretesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashesh B.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce W.","family":"Hershatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-7488","authenticated-orcid":false,"given":"Vishal R.","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen D.","family":"Godette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-4196","authenticated-orcid":false,"given":"Kamran","family":"Salari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8943-9049","authenticated-orcid":false,"given":"C. Adam","family":"Lorentz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hajiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-5298","authenticated-orcid":false,"given":"Shreyas J.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4288-5786","authenticated-orcid":false,"given":"Martin G.","family":"Sanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-2096","authenticated-orcid":false,"given":"Sagar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate Cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"10.1016\/j.clgc.2026.102556_bib0002","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.clgc.2026.102556_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300018","article-title":"Patient-reported outcomes 12 years after localized prostate cancer treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-018-2364-x","article-title":"Ablation energies for focal treatment of prostate cancer","volume":"37","author":"Lodeizen","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.euo.2020.12.008","article-title":"A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research","volume":"4","author":"Bates","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0006","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bju.14710","article-title":"Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer","volume":"124","author":"Stabile","year":"2019","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.clgc.2026.102556_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.08.011","article-title":"Salvage local treatment for recurrent prostate cancer after focal therapy: a systematic review and meta-analysis","volume":"42","author":"Takemura","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102556_bib0008","unstructured":"Bureau of Labor Statistics: Measuring Price Change in the CPI: Medical Care. United States Bureau of Labor Statistics. Available at: www.bls.gov, Accessed: August 26, 2024."},{"issue":"1","key":"10.1016\/j.clgc.2026.102556_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102556_bib0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00345-023-04354-7","article-title":"Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry","volume":"41","author":"Koelker","year":"2023","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102556_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35795","article-title":"Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States","volume":"131","author":"Sebastian","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0012","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41391-024-00907-y","article-title":"Identifying the best candidate for focal therapy: a comprehensive review","volume":"28","author":"Ghoreifi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2026.102556_bib0013","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate Cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102556_bib0014","first-page":"684","article-title":"Salvage treatments after focal therapy for prostate cancer - a comprehensive review","volume":"28","author":"Storino Ramacciotti","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2026.102556_bib0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jnci\/94.6.430","article-title":"Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy","volume":"94","author":"Potosky","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clgc.2026.102556_bib0016","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2015.08.027","article-title":"Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08","volume":"69","author":"Voog","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102556_bib0017","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102556_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.clgc.2026.102556_bib0019","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2004.08.024","article-title":"Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy","volume":"61","author":"Beyer","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"10.1016\/j.clgc.2026.102556_bib0020","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102556_bib0021","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jrr\/rrac039","article-title":"Comparing the toxicity and disease control rate of radiotherapy for prostate cancer between salvage settings after high-intensity focused ultrasound therapy and initial settings","volume":"63","author":"Kuroki","year":"2022","journal-title":"J Radiat Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102556_bib0022","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3390\/cancers15102727","article-title":"Salvage radical prostatectomy after primary Focal Ablative therapy: a systematic review and meta-analysis","volume":"15","author":"Blank","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102556_bib0023","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1038\/s41598-024-59406-8","article-title":"Salvage prostate intensity modulated radiation therapy after cryotherapy failure","volume":"14","author":"Perennec","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clgc.2026.102556_bib0024","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.euf.2021.10.005","article-title":"Outcomes of salvage robot-assisted radical prostatectomy after focal ablation for prostate cancer in comparison to primary robot-assisted radical prostatectomy: a matched analysis","volume":"8","author":"Bhat","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.clgc.2026.102556_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41391-023-00702-1","article-title":"The state of focal therapy in the treatment of prostate cancer: the University of California collaborative (UC-Squared) consensus statement","volume":"27","author":"Javier-DesLoges","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102556_bib0026","unstructured":"American Medical Association. CPT editorial summary of panel actions\u2014May 2023. Available at: https:\/\/www.ama-assn.org\/system\/files\/cpt-summary-panel-actions-may-2023.pdf. Updated June 1, 2023. Accessed: February 28, 2026."},{"key":"10.1016\/j.clgc.2026.102556_bib0027","unstructured":"American Medical Association. CPT editorial summary of panel actions\u2014September 2024. Available at: https:\/\/www.ama-assn.org\/system\/files\/sept-2024-summary-of-panel-actions.pdf. Updated October 16, 2024. Accessed: February 28, 2026."},{"issue":"6","key":"10.1016\/j.clgc.2026.102556_bib0028","first-page":"712 e1-e8","article-title":"An update on focal therapy for prostate cancer","volume":"21","author":"Perez","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102556_bib0029","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a Focal Therapy Society best practice statement","volume":"84","author":"Deivasigamani","year":"2023","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:45:40Z","timestamp":1779306340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S155876732600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102556","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102556"}}